| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sight Sciences, Inc.$5.32
+0.06 (+1.14%)
C 44Pipeline Score MedTech · Commercial
Market Cap
273.68 M
EPS
-0.71
P/E Ratio
-
Value Trade
826.13 K
SEC Financials
Q1 2026Dilution Risk
Revenue
19.70 M
R&D Expenses
2.55 M
Operating CF
-7.03 M
Total Assets
109.70 M
Total Liabilities
55.80 M
Equity
53.90 M
D/E Ratio
12,345
-2.71 %
Week
19.48 %
1 Month
-7.2 %
3 Month
-23.67 %
6 Month
-83.23 %
5 Year
-83.23 %
All Time
Cash Data
Cash Position
84.96 M
Monthly Burn
2.34 M
Runway
34.4 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
123.58 K
52 Week Range
3.11 - 9.24
% held by Insiders
35.72 %
% held by Institutions
40.87 %
Enterprise Value
229.61 M
Total Shares
54.43 M
Short %
2 %
Float Shares
36.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sight Sciences, Inc.
229Total events
0Upcoming
44Tier-1 (high impact)
2021 – 2026Coverage
Event history 229
May 26, 2026
May 13, 2026
May 6, 2026
▲IP Litigation RulingIP / Competition
Final judgment in patent infringement case against Alcon, awarding $55.4M damages and 10% ongoing royalty
glaucomasource ↗
Apr 13, 2026
◆Oral PresentationPresentation
Sight Sciences to present at 25th Annual Needham Healthcare Conference
Apr 11, 2026
◆Oral PresentationPresentation
Outcomes for Localized Heat Therapy (LHT) or Cyclosporine in Dry Eye Disease (DED) Signs and Symptoms by Baseline Severity
dry eye diseasesource ↗
Apr 2026
◆Poster PresentationPresentation
Clinically Relevant Change in Tear Break-up Time (TBUT) with Localized Heat Therapy or Cyclosporine in Dry Eye Disease (DED)
dry eye diseasesource ↗
Apr 2026
◆Poster PresentationPresentation
Longer-term Diurnal IOP (DIOP) Fluctuations Following Canaloplasty and Trabeculotomy (CT) with and without cataract surgery
primary open-angle glaucomasource ↗
Mar 27, 2026
▲IP Litigation RulingIP / Competition
Court issued order preserving jury verdict of willful infringement and awarding $34M damages plus ongoing royalty
Mar 4, 2026
▼Quarterly UpdateCorporate
Sight Sciences reported Q4 and full year 2025 financial results and initiated FY2026 guidance
Drug Pipeline Intelligence
C44
Pipeline Score $133M
Pipeline ValueValuation Signal
2
Drugs Scored0.5x
rNPV / MCap Top 64%
Micro Cap (rank 329 of 911)
Percentile RankSight Sciences, Inc. carries a moderate pipeline score (44/100), with $530M risk-adjusted pipeline value, led by BS01 in Retinitis Pigmentosa (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BS01 Monoclonal antibody | Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) | Phase 1 | NCT07158775 | 38% | $495M | RECRUITING | 40 | STALLED | C (59) | Dec 1, 2031 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OMNI Surgical System | primary open-angle glaucoma | — | 2025-02-24 | clinically and statistically significant reductions in IOP through 24 months; statistically significant reductions in medication through 36 months Read More | Sight Sciences to Present Comprehensive Clinical Data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual Meeting Read More | |
OMNI Surgical System | primary open-angle glaucoma | — | 2025-02-24 | clinically and statistically significant reductions in IOP through 24 months; statistically significant reductions in medication through 36 months Read More | Sight Sciences to Present Comprehensive Clinical Data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual Meeting Read More | |
OMNI Surgical System | primary open-angle glaucoma | — | 2025-02-24 | clinically and statistically significant reductions in IOP through 24 months; statistically significant reductions in medication through 36 months Read More | Sight Sciences to Present Comprehensive Clinical Data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SGHT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SGHT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SGHTSight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
Sight Sciences reported a strong start to 2026, with a 13% increase in revenue to $19.7 million in Q1. The company also raised its full-year revenue guidance, driven by significant growth in Interventional Dry Eye products. Despite a net loss of $13.0 million, the company demonstrated improved cash management and operational efficiency.
Read more →SGHT▼ -8.9%on this news
Sight Sciences to Present at Two Upcoming Investor Conferences
Sight Sciences, an eyecare technology company, announced its participation in two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026. The company focuses on developing innovative technologies aimed at transforming eye care, particularly addressing prevalent eye diseases. Interested parties can access webcasts of the presentations on their investors' page.
Read more →SGHTSight Sciences Announces the Release of its Sustainability Report
Sight Sciences, an eyecare technology firm, has released its third annual Sustainability Report, which outlines its environmental and social initiatives over the past three years. The report highlights significant progress in transparency, operational discipline, and a more than 20% reduction in emissions in 2025. Additionally, the company has supported various community engagement programs, donating to initiatives that aid indigent care in 24 different countries. With a workforce where 56% are women, Sight Sciences emphasizes its commitment to diversity and effective governance practices.
Read more →SGHTSight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
Sight Sciences, Inc. announced it will report its first quarter financial results for 2026 on May 6, 2026, after market close. The management will host a conference call to discuss the results at 1:30 p.m. PT. The company specializes in innovative eyecare technologies aimed at improving patient care.
Read more →SGHTSight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences, Inc. will present data on its glaucoma and dry eye technologies at the 2026 ASCRS Annual Meeting. The OMNI Surgical System and TearCare System will be highlighted, showcasing their effectiveness in reducing intraocular pressure and improving tear film stability. The presentations aim to support broader adoption of these technologies among eyecare providers.
Read more →SGHT▼ -5.2%on this newsshared move
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Sight Sciences has secured a favorable ruling from the U.S. District Court, which upheld the jury's verdict of willful patent infringement by Alcon regarding its Hydrus Microstent. The court awarded Sight Sciences $34 million in damages and established ongoing royalties of 10% on Hydrus sales until the expiration of its last asserted patent in 2028. However, the final judgment is subject to appeal and may be influenced by ongoing reexamination proceedings initiated by Alcon.
Read more →SGHT▼ -5.2%on this newsshared move
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Sight Sciences, Inc. announced its participation in the 25th Annual Needham Healthcare Conference, scheduled for April 13, 2026. The presentation will be accessible via a live and archived webcast. The company specializes in developing innovative eyecare technologies aimed at improving patient outcomes, particularly in glaucoma and dry eye disease treatments.
Read more →SGHT▼ -6.3%on this news
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of Sight Sciences investors who have experienced losses. This comes after the company revealed its 2025 financial results and anticipated revenue for 2026, which led to a significant decline in stock price. The investigation aims to determine if the company adhered to federal securities laws, which could impact the ability of lost investors to recover their losses.
Read more →SGHT▼ -26.8%on this newsshared move
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
Sight Sciences reported its financial results for Q4 and full year 2025, highlighting a 7% revenue increase in Q4. The company also initiated guidance for 2026, projecting revenue growth of 6% to 14%. Despite a net loss of $38.4 million for 2025, management remains optimistic about achieving cash flow breakeven in the coming year.
Read more →SGHTSight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Sight Sciences, Inc. has announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on March 4, 2026. The report will follow a conference call scheduled for 1:30 p.m. PT, where management will discuss the results. The company's focus on innovative, minimally invasive eyecare technologies aims to improve patient care and align with advancements in treatment modalities for prevalent eye diseases.
Read more →SGHT▼ -7.8%on this news
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2025, indicating a 7% revenue growth in Q4 but a 3% decrease for the full year. The company maintains a strong cash position of approximately $92 million and has made significant progress in Dry Eye reimbursement. Full financial results are expected in March 2026.
Read more →SGHT▲ +8%on this news· ran to +18% by day 1
New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
Sight Sciences, Inc. has announced positive results from three peer-reviewed studies on its OMNI Surgical System with TruSync Technology. The studies highlight the system's effectiveness in reducing intraocular pressure and medication reliance in glaucoma patients, particularly among African Americans. The findings support the use of interventional treatments in managing glaucoma.
Read more →SGHT▲ +16.4%on this news· ran to +54% by day 3shared move
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
Sight Sciences, Inc. reported its third-quarter financial results for 2025, revealing a slight revenue decline but an increase in Surgical Glaucoma revenue. The company raised its full-year revenue guidance and reduced its operating expenses, reflecting operational efficiencies. However, the Dry Eye segment faced significant revenue challenges, impacting overall financial performance.
Read more →SGHT▲ +16.4%on this news· ran to +54% by day 3shared move
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
Sight Sciences has appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer, effective November 5, 2025. Both leaders bring extensive experience in medtech and finance, which aligns with the company's goals to enhance its market position and improve patient care. The appointments are seen as crucial for scaling operations and driving growth in the interventional dry eye category.
Read more →SGHTSight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
Sight Sciences, Inc. will announce its third quarter financial results on November 6, 2025. The results will be discussed in a conference call at 1:30 p.m. PT. Investors can access a live and archived webcast of the call on the company's website. Sight Sciences specializes in developing innovative eyecare technologies.
Read more →SGHT▲ +35.9%on this news· ran to +49% by day 3
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
Sight Sciences announced that Novitas Solutions and First Coast Service Options have established a fee schedule for the TearCare procedure, effective January 1, 2025. This pricing will facilitate Medicare claims processing for the procedure, which targets dry eye disease. The company aims to enhance patient access through collaboration with eyecare providers and stakeholders.
Read more →SGHTSight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
Sight Sciences announced a systematic review and meta-analysis published in the European Journal of Ophthalmology, demonstrating that the OMNI Surgical System effectively reduces intraocular pressure and medication use in patients with open-angle glaucoma. The study involved 29 publications and highlighted the long-term benefits and safety of the treatment. The findings were presented at a recent ophthalmology meeting in Copenhagen.
Read more →SGHTSight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments
Sight Sciences announced that UnitedHealthcare will expand its coverage to include the OMNI Surgical System for glaucoma treatments. Effective October 1, 2025, this policy will cover various minimally invasive glaucoma surgeries for adults deemed medically necessary. This change is expected to enhance patient access to innovative treatment options.
Read more →SGHTSight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO
Sight Sciences' TearCare System has been recognized in the TFOS DEWS III report published in the American Journal of Ophthalmology. This inclusion marks a significant validation of its clinical efficacy in managing meibomian gland disease (MGD). The report is influential for clinicians in refining treatment algorithms for dry eye disease.
Read more →SGHTSight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences, Inc. will present at the Morgan Stanley Global Healthcare Conference on September 10, 2025. The company aims to showcase its innovative eyecare technologies designed to improve patient outcomes. Interested parties can access the presentation via a live and archived webcast on their website.
Read more →SGHTSight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
Sight Sciences, Inc. reported its second quarter 2025 financial results, highlighting an 8% revenue decrease to $19.6 million, primarily driven by lower sales in its Surgical Glaucoma segment. Despite this, the company raised its revenue guidance for the full year 2025 to between $72.0 million and $76.0 million. Management emphasized a growing number of surgical glaucoma ordering accounts and showed promising results from the TearCare System, which aided in treating dry eye disease. However, the firm faces challenges like recent Medicare coverage restrictions and a reported net loss.
Read more →SGHTSight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
Sight Sciences, Inc. announced the results of a cost-utility analysis demonstrating that its TearCare system is more cost-effective than cyclosporine 0.05% for treating dry eye disease associated with meibomian gland disease. The analysis revealed TearCare resulted in lower annual treatment costs and higher quality-adjusted life years (QALYs). This reinforces the system's economic sustainability and clinical effectiveness compared to traditional therapies. The findings are seen as a significant advancement for both patient care and healthcare economics.
Read more →SGHTSight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare Procedure for the Treatment of Dry Eye Disease
Sight Sciences, Inc. has released positive findings from the 24-month follow-up of the SAHARA randomized controlled trial, evidencing the TearCare procedure's durability in treating dry eye disease. The peer-reviewed manuscript published in Optometry and Vision Science confirms sustained improvements in both symptoms and clinical signs with a majority of participants requiring no further treatment after initial applications. These results suggest that TearCare offers a promising long-term solution for patients suffering from dry eye disease.
Read more →SGHT▼ -5.8%on this newsshared move
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
Sight Sciences, an eyecare technology company, has announced that it will report its second-quarter financial results for 2025 on August 7, 2025. The results will be discussed during a conference call scheduled for the same afternoon. The company specializes in developing innovative, minimally invasive solutions for eye diseases, aiming to improve patient care and outcomes.
Read more →SGHTSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, has announced its participation in the Stifel 2025 Virtual Ophthalmology Forum scheduled for May 27, 2025. Management will present at 9:00 AM PT and a webcast will be available on the company’s investor website. The presentation is part of Sight Sciences' ongoing efforts to highlight their innovative interventional technologies designed to transform eye care and improve patient outcomes.
Read more →SGHT▲ +5.9%on this news· ran to +20% by day 3
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
Sight Sciences reported its first quarter 2025 financial results, revealing a revenue of $17.5 million, a 9% decrease year-over-year. The decline was largely attributed to lower revenues in the Surgical Glaucoma segment due to new Medicare limitations. Despite the revenue drop, the company has successfully launched its OMNI Edge product and reduced operating expenses. The outlook for full-year 2025 reflects anticipated revenue declines due to ongoing reimbursement issues.
Read more →SGHTSight Fresh Himalayan Fruit Jam: Naturally Repair Blurry Eyesight
The article presents Sight Fresh Himalayan Fruit Jam, a natural supplement designed to address blurry vision and digital eye fatigue. The product is formulated with various Himalayan superfruits such as goji berries and turmeric, which are claimed to support eye health. Unlike traditional synthetic eye treatments, this jam provides nutrients in an easily consumable form, appealing to health-conscious consumers. The article also emphasizes the rise of visual problems linked to modern screen use and nutritional deficiencies.
Read more →SGHTSightFresh Under Review: Secret Vision Berry to Restore Eyesight with Sight Fresh Ingredients
SightFresh is a new eye health supplement launched in 2025, designed to support clearer vision and ocular wellness using a natural blend of ingredients, including the notable Secret Vision Berry. The product aims to address increasing vision problems attributed to factors like digital screen exposure and aging. While encouraging positive user feedback and claims of effectiveness, it also notes the variability of results among individuals and stresses that it does not serve as a pharmaceutical remedy for eye diseases. The supplement is manufactured under strict guidelines to ensure quality and safety.
Read more →SGHTSight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025
Sight Sciences, Inc. has announced that it will report its financial results for the first quarter of 2025 on May 8, 2025. The results will be shared after market close, followed by a conference call with management at 1:30 p.m. PT. The company's emphasis on developing interventional eyecare technologies reflects its goal to transform patient care and improve treatment outcomes for prevalent eye diseases.
Read more →SGHT▲ +8.3%on this newsshared move
Sight Sciences Appoints Gary Burbach to its Board of Directors
Sight Sciences has appointed Gary Burbach to its Board of Directors, effective April 21, 2025. With extensive experience in the medtech industry, including a successful tenure as CEO of Thoratec, Burbach is expected to contribute significantly to the company's strategy in the surgical glaucoma and dry eye markets. His insights and leadership are anticipated to aid in Sight Sciences' mission to innovate and improve patient care.
Read more →SGHTSight Sciences to Debut OMNI Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio
Sight Sciences, Inc. (Nasdaq: SGHT) is set to launch the OMNI Edge Surgical System at the 2025 ASCRS Annual Meeting in Los Angeles. This new system enhances the existing OMNI product portfolio with improved viscoelastic delivery capabilities and is designed for versatility in treating primary open-angle glaucoma. The OMNI Edge aims to offer a comprehensive solution for glaucoma care by addressing key resistance areas in the eye, making it suitable for standalone or combined procedures with cataract surgery. The technology is exclusively available in the United States.
Read more →SGHT▼ -12.4%on this news
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
Sight Sciences, Inc. announces its upcoming presentation at the 24th Annual Needham Healthcare Conference on April 8, 2025. The event will be held virtually, and interested viewers can access the live and archived webcast through the company's website. Sight Sciences is dedicated to developing innovative eyecare technologies aimed at transforming care for eye diseases, including its advanced surgical systems and therapies for glaucoma and dry eye disease.
Read more →SGHTSight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance
Sight Sciences, Inc. reported its fourth quarter and full year 2024 financial results, indicating a stable revenue performance with key metrics showing marginal fluctuations. Notably, revenue for Q4 2024 was $19.1 million, marking a slight increase from the previous year, while full year revenue fell by 1% to $79.9 million. The company also reported a reduced net loss and significant improvements in cash management. Looking forward, it has provided financial guidance for 2025, anticipating a 6% to 12% decline in revenue.
Read more →SGHTSight Sciences to Present Comprehensive Clinical Data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual Meeting
Sight Sciences, Inc. announced that it will present comprehensive clinical data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual Meeting. The data reaffirms the safety and clinical effectiveness of OMNI in treating primary open-angle glaucoma, supported by a meta-analysis of 22 studies. Findings indicate significant long-term reductions in intraocular pressure and medication reliance among diverse patient populations. Presentations will showcase insights from real-world data and systematic reviews, emphasizing OMNI's role in glaucoma care.
Read more →SGHTSight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025
Sight Sciences, Inc. has announced plans to report its financial results for the fourth quarter and full year 2024 on March 5, 2025. Following the announcement, management will host a conference call to discuss the results. The company emphasizes its focus on innovative eyecare technology aimed at improving patient care, particularly in treating conditions like glaucoma and dry eye disease.
Read more →SGHT▲ +7%on this newsshared move
Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day
Sight Sciences, Inc. announced its participation in Citi's 2025 Unplugged MedTech and Life Sciences Access Day scheduled for February 27, 2025. The presentation will showcase the company's innovative eyecare technologies aimed at transforming patient care. Their products, including the OMNI® Surgical System and TearCare® System, target significant eye diseases, including glaucoma and dry eye disease. A live and archived webcast will be available on the company's investor relations website.
Read more →SGHT▲ +7%on this newsshared move
Sight Care – Study Findings, Reviews, Ingredients and Where to Buy It
Sight Care launches an innovative vision-support product that promotes eye health through a simple 7-second nightly ritual. Co-founder David Lewis, once an eye care specialist, shares his personal story of vision loss, advocating for natural remedies over conventional eye care solutions. The product targets the root causes of vision decline by utilizing adult repair stem cells and emphasizes a holistic approach. With rising concerns over digital eye strain, Sight Care seeks to redefine vision support for individuals of all ages.
Read more →SGHTSight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Sight Sciences reported preliminary financial highlights for Q4 and full year 2024, signaling a mixed performance. While surgical glaucoma revenues showed a 9% increase, total revenues are down 2% annually. The reduction in cash use reflects improved operational discipline, yet significant revenue declines were noted in the dry eye segment. The Company aims to achieve cash flow breakeven without raising additional equity capital, maintaining a strong cash position ahead of the full financial report in March 2025.
Read more →SGHTSight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma
Sight Sciences, Inc. announced a 36-month study demonstrating the long-term effectiveness of its OMNI Surgical System in managing primary open-angle glaucoma. The study, featuring 230 eyes from 196 patients, showed significant reductions in intraocular pressure and medication use. These findings underscore the capability of the OMNI system to provide sustained patient benefits without the need for cataract surgery, suggesting its potential as a leading solution in minimally invasive glaucoma surgery.
Read more →SGHTSight Sciences Announces the Results of a Budget Impact Analysis for its TearCare System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
Sight Sciences, Inc. has released a Budget Impact Analysis for its TearCare System, indicating potential annual cost savings of $36.87 per member when adopted over existing dry eye medications. The analysis forecasts these results based on a 20% increase in the market share of TearCare among moderate to severe Meibomian gland dysfunction patients. Strong clinical data from previous trials support these findings, suggesting a favorable economic impact for payors considering reimbursement for TearCare treatments. The study emphasizes the importance of this innovative technology in addressing dry eye disease in the U.S.
Read more →SGHTSight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Sight Sciences, Inc. (Nasdaq: SGHT) announced its participation at the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3, 2024, in New York. The presentation will be accessible through a live and archived webcast on the company's investor website. Sight Sciences specializes in developing interventional technologies aimed at enhancing eye care, particularly through minimally invasive solutions for conditions like glaucoma and dry eye disease.
Read more →SGHT▼ -8.2%on this news
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations
Sight Sciences has appointed MK Raheja as Executive Vice President of Research and Development and Brenton Taylor as Executive Vice President of Operations, effective November 4, 2024. This leadership change follows the upcoming retirement of Sam Park, the current COO. The new executives are expected to leverage their substantial industry experience to enhance the company's innovation pipeline and scale operations effectively. Sight Sciences aims to continue transforming treatment paradigms in eyecare with these new appointments.
Read more →SGHT▼ -8.2%on this news
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance
Sight Sciences, Inc. (NASDAQ: SGHT) reported its financial results for Q3 2024, showing a slight revenue increase to $20.2 million and a positive cash flow of $0.4 million compared to a loss in the prior year. The company confirmed Medicare coverage for specific MIGS procedures, potentially enhancing their market position. However, CEO Paul Badawi noted that the recovery in Surgical Glaucoma did not meet expectations, and Dry Eye revenue is expected to decline due to fewer new accounts. The company has reduced its adjusted operating expense guidance for the full year 2024, reflecting improved cost management and operational discipline.
Read more →SGHTSight Sciences to Report Third Quarter Financial Results on November 7, 2024
Sight Sciences, Inc. (Nasdaq: SGHT) announced that it will report its third quarter financial results for 2024 on November 7, 2024, after market close. The company's management will hold a conference call at 1:30 p.m. PT to discuss these results. Investors can access a live webcast of the event on the company's website, which will be available for replay for at least 90 days. The company focuses on developing innovative technologies to treat prevalent eye diseases.
Read more →SGHTSight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance
Sight Sciences, Inc. reported its second quarter 2024 financial results, highlighting a total revenue of $21.4 million, an 11% quarter-over-quarter increase despite a 9% year-over-year decrease. The company narrowed its full-year revenue guidance to approximately $81.0 million to $83.0 million, reflecting expected growth of 0% to 2%. Notably, cash usage decreased by 29%, while Surgical Glaucoma account utilization increased, suggesting a recovery in that segment. However, the decline in Dry Eye revenue and anticipated negative impacts from an upcoming price increase were also noted.
Read more →SGHT▼ -6.1%on this news
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
Sight Sciences, Inc. (Nasdaq: SGHT) has announced that it will report its financial results for the second quarter ended June 30, 2024, following the market close on August 1, 2024. The company's management will discuss these results during a conference call at 1:30 p.m. PT. Investors can access the live and archived webcast through the company's website. Sight Sciences is focused on developing innovative solutions for treating common eye diseases, with products like the OMNI and TearCare systems aimed at improving patient care.
Read more →SGHTSight Sciences Announces the Release of its First Sustainability Report
Sight Sciences, Inc. has published its first Sustainability Report, showcasing its commitment to sustainability over the past three years. This report details environmental initiatives aimed at reducing the company's impact, along with social responsibility efforts supporting diversity and community engagement. Highlights include the launch of a Women in Leadership initiative and a notable representation of women on the board. The company continues to focus on innovative eyecare technologies while aligning its practices with corporate sustainability goals.
Read more →SGHT▲ +7.5%on this news· ran to +18% by day 3
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Sight Sciences announced the publication of twelve-month results from the SAHARA RCT, demonstrating that patients previously treated with Restasis experienced enhanced signs and symptoms of dry eye disease upon switching to TearCare. This crossover showed sustained improvements in tear break-up time and other objective measures, underscoring the potential of TearCare as a viable alternative treatment. The results, indicating superior effectiveness of TearCare, also highlight its benefits in patient adherence compared to prescription-based solutions. The study is set to proceed into Phase 3 for long-term data collection.
Read more →SGHT▲ +7.5%on this news· ran to +18% by day 3
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI Across Mild, Moderate, and Advanced Glaucoma
Sight Sciences, Inc. announced new findings from the ROMEO study, showing that its OMNI Surgical System effectively reduces intraocular pressure and medication requirements in patients with mild, moderate, and advanced glaucoma. The study, published in Clinical Ophthalmology, reveals that advanced glaucoma patients can achieve successful treatment outcomes, contradicting prior assumptions about the efficacy of minimally invasive procedures in severe cases. Over 70% of participants saw reductions in IOP after 12 months, with most reaching levels of 18 mmHg or less.
Read more →SGHTSight Sciences to Present at the Upcoming Bank of America Healthcare Conference
Sight Sciences, Inc. will participate in the Bank of America Healthcare Conference scheduled for May 14, 2024. The presentation will be available through a live and archived webcast on the company's investors webpage. Sight Sciences is recognized for its innovative eyecare technologies including the OMNI Surgical System and TearCare System, which enhance treatment for glaucoma and dry eye disease. The company's focus is on transforming care standards within the eyecare sector.
Read more →SGHTSight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
Sight Sciences, Inc. reported its financial results for Q1 2024, showcasing a revenue increase of 2%, with a gross margin improvement to 86%. The company reaffirmed its full-year guidance, projecting revenue growth of 0% to 5%. Significant operational discipline is noted with a 39% decrease in cash usage year-over-year. A favorable jury trial verdict regarding patent infringement against Alcon highlights their legal progress, despite challenges in the Dry Eye segment, where revenue fell 32% compared to the previous year.
Read more →SGHT▲ +10.2%on this newsshared move
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
Sight Sciences has announced a significant legal victory in its patent infringement case against Alcon, resulting in a $34 million jury verdict. This award was given after a trial where the jury found that Alcon willfully infringed upon three key patents held by Sight Sciences regarding its Hydrus Microstent technology for glaucoma treatment. The damages awarded include both lost profits and royalties. The outcome underscores Sight Sciences' investment in research and development aimed at advancing glaucoma care and protecting its intellectual property.
Read more →SGHTSight Sciences to Report First Quarter Financial Results on May 2, 2024
Sight Sciences, Inc. (SGHT) will announce its financial results for the first quarter ending March 31, 2024, on May 2, 2024, after market close. A conference call is scheduled for the same day at 1:30 p.m. Pacific Time, where management will discuss the results. The company specializes in developing interventional technologies aimed at improving patient care in eyecare, particularly for glaucoma and dry eye diseases. Interested investors can access a live or archived webcast of this event on their investor relations webpage.
Read more →SGHTSight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences announced the results of a large-scale study published in the American Journal of Ophthalmology, focusing on the OMNI Surgical System's effectiveness in treating glaucoma. The study evaluated long-term outcomes in patients who underwent minimally invasive glaucoma surgery combined with cataract surgery. Findings indicated significant reductions in intraocular pressure and the number of IOP-lowering medications after two years. The research suggests that OMNI technology could offer meaningful improvements for glaucoma management in a real-world setting.
Read more →SGHTSight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences, Inc. announced positive results from the three-year prospective GEMINI trial and the cross-over phase of the SAHARA RCT. Data show the long-term efficacy of the OMNI Surgical System for the treatment of primary open-angle glaucoma, along with supportive evidence for the TearCare technology as a primary treatment for dry eye disease. These findings will be presented at the 2024 ASCRS Annual Meeting in Boston, enhancing the company's clinical evidence and positioning in the eyecare market.
Read more →SGHTSight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
Sight Sciences, Inc. has announced its upcoming presentation at the 23rd Annual Needham Healthcare Conference, scheduled for April 9, 2024. The event will be held virtually, and interested participants can access the presentation through the company's website. As an eyecare technology company, Sight Sciences aims to develop innovative interventional technologies to enhance patient care in the field of eye health.
Read more →SGHTSight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
Sight Sciences, Inc. has reported its financial results for Q4 and the full year of 2023, highlighting a 14% increase in yearly revenue but a 9% decline in Q4 revenue. The company significantly reduced its operating expenses by 20% in Q4 and decreased annual cash usage. A senior secured credit facility was closed to further strengthen its financial position. Additionally, Sight Sciences successfully maintained Medicare access to vital surgical tools, indicating future operational stability despite recent challenges.
Read more →SGHTSight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
Sight Sciences, Inc. (Nasdaq: SGHT) has announced that it will report its financial results for the fourth quarter and full year of 2023 on March 7, 2024, after market close. The company's management will hold a conference call to discuss these results at 1:30 p.m. Pacific Time. Sight Sciences focuses on developing innovative technologies for eyecare, including treatments for glaucoma and dry eye disease, highlighting its role in improving patient care and transforming treatment paradigms.
Read more →SGHTSight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting
Sight Sciences, Inc. has launched the Ergo-Series of the OMNI Surgical System in Europe at the ESCRS Winter Meeting. This system facilitates minimally invasive glaucoma procedures and was previously launched in the United States in March 2023, receiving positive feedback from surgeons. The new design emphasizes improved ergonomics and a more intuitive operation, aiming to enhance surgical outcomes for patients with open-angle glaucoma. The launch follows the granting of CE Mark under the new EU Medical Device Regulation.
Read more →SGHT▼ -9.7%on this news· ran to -23% by day 3
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital Refinancing replaces prior senior credit facility
Sight Sciences, Inc. has announced the closing of a senior secured credit facility of up to $65 million with Hercules Capital. The facility replaces an existing credit agreement and includes an immediate draw of $35 million, which has already been used to pay off previous debts. The CFO of Sight Sciences expressed confidence that the partnership with Hercules will enhance financial flexibility and support the company's mission of transforming eye care. This capital will help the company in its efforts to address underlying causes of prevalent eye diseases.
Read more →SGHTSight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
Sight Sciences, Inc. announced preliminary financial highlights for the fourth quarter and full year ended December 31, 2023. For Q4, total revenue is expected to be approximately $18.6 million to $18.8 million, which is a 9% decrease from the previous year. In contrast, full year revenues showed a 14% increase, reaching between $80.9 million to $81.1 million. The company reported operational improvements, with cash used significantly reduced compared to both Q3 2023 and Q4 2022.
Read more →SGHT▼ -5.6%on this news
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
Sight Sciences, Inc. announced that five Medicare Administrative Contractors have withdrawn their final local coverage determinations for Micro-Invasive Glaucoma Surgery, which were due to take effect on January 29, 2024. This decision means that there will be no changes in Medicare coverage for procedures using the OMNI Surgical System at this time. The company hopes to maintain favorable access to MIGS procedures through ongoing collaboration with MACs and CMS. The withdrawal reflects careful consideration of stakeholder concerns regarding patient health and care access.
Read more →SGHTSight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease
Sight Sciences, Inc. announced the publication of positive results from the SAHARA randomized controlled trial, which compared the effectiveness of its TearCare technology with Restasis for the treatment of dry eye disease. The trial demonstrated that TearCare outperformed Restasis in improving tear break up time and other significant indicators of eye health. The company plans to present these results to Medicare and commercial payors to facilitate market access for its innovative technology. The SAHARA trial included 345 participants and showed meaningful improvements for patients using TearCare.
Read more →SGHT▲ +8.3%on this news· ran to +19% by day 3
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI Surgical System Technology
Sight Sciences announced the acceptance for publication of the GEMINI 2 trial results, demonstrating long-term effectiveness of the OMNI Surgical System in reducing intraocular pressure (IOP). The trial showed that 77% of patients were medication-free at two years and 74% at three years, indicating sustained medication reduction. Results confirm previous findings from the 12-month GEMINI trial, suggesting strong safety and effectiveness of the procedure. The publication of these findings is anticipated by December 31, 2023.
Read more →SGHT▲ +22.1%on this news
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
Sight Sciences, Inc. reported its Q3 2023 financial results, showing a year-over-year revenue increase of 7% to $20 million and an improved gross margin of 86.6%. However, the company withdrew its guidance for the full year 2023 due to uncertainties surrounding new LCDs that limit Medicare coverage for certain procedures. The net loss for Q3 was $13 million, reflecting ongoing operational challenges, although the company is implementing cost-reduction measures to extend cash runway. New leadership has been appointed to enhance growth strategies amidst these changes.
Read more →SGHTSight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
Sight Sciences, Inc. (Nasdaq: SGHT) will report its third quarter 2023 financial results on November 7, 2023, after market close. The management will hold a conference call to discuss these results, which will begin at 1:30 p.m. PT. The company specializes in innovative eyecare technology aimed at improving patient care through minimally invasive procedures. They offer products such as the OMNI® Surgical System for glaucoma treatment and the TearCare System for dry eye disease.
Read more →SGHT▼ -6.6%on this newsshared move
Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
Sight Sciences, Inc. will host a reception in San Francisco on November 3, 2023, to present the results of its TearCare SAHARA Six Month RCT. The event will involve a formal presentation followed by a live Q&A session, emphasizing the company's commitment to innovative eye care technologies. Registration for in-person attendance is required, reflecting the event's exclusive nature. The company's focus on developing advanced treatments underscores its mission to enhance patient care in ophthalmology.
Read more →SGHTSight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
Sight Sciences announced the successful results of its Phase I SAHARA trial, showing that TearCare technology outperformed Restasis in improving tear break up time for dry eye disease. The study included 345 participants and demonstrated significant enhancements in objective measures of dry eye health. Presented at the American Academy of Optometry Annual Meeting, these findings suggest a shift towards interventional eyelid procedures as potentially superior to conventional eyedrop treatments. The trial's data is expected to be published in a peer-reviewed journal later this year.
Read more →SGHT▲ +5.9%on this news· ran to +30% by day 3
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Sight Sciences announced positive results from a large-scale study presented at the ESCRS Congress, demonstrating that their OMNI Surgical System technology effectively lowers intraocular pressure and reduces medication use for glaucoma patients over two years. The study involved 77,391 patients and compared outcomes with other minimally invasive glaucoma surgery options. The findings support the TCOR procedure as a leading approach in glaucoma treatment, showing significant improvements in patient outcomes.
Read more →SGHT▲ +6%on this news· ran to -47% by day 1
Sight Sciences Appoints Matt Link as Chief Commercial Officer Former NuVasive President helped scale high-growth medical device company to over $1 billion in revenue
Sight Sciences has appointed Matt Link as Chief Commercial Officer, effective September 11, 2023. Link, formerly president at NuVasive, is expected to drive growth in the company's Surgical Glaucoma and Dry Eye divisions. With over 20 years of experience in the medical technology sector, Link aims to leverage his expertise to advance Sight Sciences' strategic objectives and improve patient care with innovative surgical technologies.
Read more →SGHT▲ +6%on this news· ran to -47% by day 1
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
Sight Sciences, Inc. has announced its revenue guidance for the third quarter of 2023, projecting total revenue between $19.0 million and $20.0 million. The company has also updated its forecast for the full year, estimating revenues of $80.0 million to $82.0 million, reflecting approximately 12% to 15% growth compared to the previous year. While the company maintains high account retention, it faces challenges such as reduced new account additions and decreased utilization attributed to uncertainty from proposed local coverage determinations. The company believes that these impacts may be transitory if coverage for its OMNI procedures remains secure.
Read more →SGHTSight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
Sight Sciences, Inc. will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023. The presentation will showcase the company's commitment to transforming eye care through innovative technology. Notably, their products include the OMNI Surgical System for glaucoma and the TearCare System for dry eye disease. This event offers a platform for the company to enhance its profile among investors and industry stakeholders.
Read more →SGHTSight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
Sight Sciences, Inc. reported strong financial results for the second quarter of 2023, achieving record revenues of $23.5 million, a 36% increase compared to the prior year. The company reaffirmed its guidance for full-year revenues, expecting a growth range of 25% to 32%. The results were bolstered by successful clinical trial outcomes for its TearCare technology and expanded access to its OMNI Surgical System for glaucoma procedures. Despite showing revenue growth, the company recorded a net loss of $14.8 million in the quarter.
Read more →SGHTSight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare Technology to Restasis for the Treatment of Dry Eye
Sight Sciences, Inc. announced positive results from the SAHARA clinical trial, which compared its TearCare technology with Restasis for treating dry eye disease. The trial met its primary six-month endpoint, showing TearCare's effectiveness in improving tear break up time and other key measures. Findings indicated that interventional eyelid procedures with TearCare were superior to Restasis in treating dry eye symptoms. The data supports a shift in treatment paradigms towards procedural interventions rather than traditional eye drops.
Read more →SGHTSight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
Sight Sciences, Inc. will report its second quarter financial results for 2023 on August 3, following the market close. The announcement includes a conference call scheduled for 1:30 p.m. Pacific Time, where management will discuss the results. The company specializes in innovative solutions for eyecare, including minimally invasive technologies aimed at treating prevalent eye diseases. Investors can access a live webcast of the call and a replay will be available for at least 90 days.
Read more →SGHTSight Sciences Announces Addition of New Director Catherine Mazzacco
Sight Sciences announced the election of Catherine Mazzacco to its board of directors during its Annual Meeting of Stockholders. Mazzacco, an experienced leader in the healthcare sector, is expected to provide strategic insight that will support the company's growth and expansion efforts. Her background includes former leadership roles at Abbott and GE HealthCare, which are relevant to the company's goals in the glaucoma and dry eye treatments. The company aims to improve standards of care and enhance patient lives through its innovative eyecare solutions.
Read more →SGHTSight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI Surgical System Technology
Sight Sciences, Inc. announced the two-year results of the ROMEO study, demonstrating sustained reductions in intraocular pressure (IOP) and medication use for patients with mild to moderate primary open-angle glaucoma treated with the OMNI Surgical System. The data showed that significant improvements observed at 12 months were maintained through 24 months, confirming the safety and efficacy of the technology. This study represents the longest multicenter clinical results for the OMNI system and provides eye surgeons with greater confidence in its long-term effectiveness.
Read more →SGHT▲ +5.2%on this news
Delivering the Power of Sight Investor Presentation May 2023 Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-loo
Sight Sciences recently presented information about its operations, highlighting a strong market potential for its glaucoma and dry eye treatments. The presentation emphasized ongoing initiatives aimed at expanding their product portfolio and increasing market share. Despite the optimistic outlook, the company acknowledged certain risks and uncertainties related to forward-looking statements. Overall, the investor presentation outlines the company's strategy and its commitment to innovation in the eye care sector.
Read more →SGHT▲ +5.2%on this newsshared move
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS Registry
Sight Sciences, Inc. announced positive results from a 12-month study analyzing IOP-lowering medication use in mild glaucoma patients. The study, involving 16,789 patients, showed that those treated with the OMNI Surgical System had a significant reduction in medication requirements compared to other FDA-approved MIGS procedures. These findings highlight the potential of OMNI technology to improve treatment approaches and reduce patient medication burden. The data will be presented at the ASCRS annual meeting, indicating significant implications for glaucoma management in real-world settings.
Read more →SGHT▲ +6.3%on this newsshared move
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
Sight Sciences, Inc. reported its financial results for Q1 2023, revealing a revenue increase of 26% to $18.8 million over the previous year. The company has reaffirmed its guidance for full-year revenue, expecting growth of approximately 25% to 32% compared to 2022. Significant advancements included a rise in gross margin to 84% and the launch of the Ergo-Series OMNI Surgical System. Despite these positives, the company reported a net loss of $17.1 million.
Read more →SGHT▲ +9.4%on this newsshared move
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences, Inc. will showcase its glaucoma and dry eye technologies, the OMNI Surgical System and TearCare System, at the 2023 ASCRS Annual Meeting. The presentations will include original data analyses from the IRIS Registry, illustrating the efficacy of their technologies compared to traditional methods. The event provides a platform for physicians to discuss advancements in minimally invasive glaucoma surgery. Key presentations will focus on clinical outcomes and new treatment paradigms related to both systems.
Read more →SGHT▲ +5.2%on this newsshared move
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
Sight Sciences, Inc. (SGHT) will present at the Bank of America Securities 2023 Health Care Conference on May 10, 2023. The presentation will showcase the company's innovative eyecare solutions aimed at improving patient lives. Notably, Sight Sciences focuses on minimally invasive techniques for treating prevalent eye diseases like glaucoma and dry eye disease. Investors can access the presentation through a live webcast on the company’s website.
Read more →SGHTSight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
Sight Sciences, Inc. (Nasdaq: SGHT) announced it will report its financial results for the first quarter ending March 31, 2023, on May 4, 2023, after market close. The management will host a conference call to discuss the results at 1:30 p.m. PT. The company specializes in eyecare technology, focusing on innovative solutions to improve patient care and treat common eye diseases. Interested investors can access the call through a live and archived webcast available on the company's website.
Read more →SGHT▲ +6.3%on this news
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
Sight Sciences, Inc. will host a Surgical Glaucoma Investor Symposium in San Diego, CA on May 5, 2023. The event is set to feature presentations from recognized surgeons and remarks by the company's executive management team. Attendance requires prior registration due to limited space, and a live webcast will be available following the event. This initiative underlines Sight Sciences' commitment to advancing eyecare technologies that significantly enhance patient treatment outcomes.
Read more →SGHTSight Sciences Appoints Ali Bauerlein as Chief Financial Officer
Sight Sciences, Inc. has appointed Ali Bauerlein as Chief Financial Officer, effective April 3, 2023. Bauerlein brings extensive experience from her previous role at Inogen, where she significantly grew the company's financial operations. Her leadership is expected to drive profitable growth and enhance the financial infrastructure of Sight Sciences. The company aims to develop innovative eyecare solutions that can disrupt two multibillion-dollar markets.
Read more →SGHTSight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
Sight Sciences, Inc. has successfully defeated invalidity challenges against its patents filed by Alcon and Ivantis at the U.S. Patent Office. The Patent Office ruled that the prior art presented did not warrant a review of the patents. This decision strengthens Sight Sciences' position in ongoing patent infringement litigation, as they pursue claims against Alcon and Ivantis. A jury trial is scheduled for April 2024 to address these infringement claims.
Read more →SGHTSight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
Sight Sciences reported its financial results for Q4 2022 and the full year, revealing a 46% revenue increase compared to 2021. The company generated a total revenue of $71.3 million in 2022, with notable growth in both its Surgical Glaucoma and Dry Eye segments. Despite these positive trends, the company also faced significant net losses, which increased year-over-year. Management provided financial guidance projecting revenue growth for 2023 and emphasized a focus on sustainable growth while managing operating expenses more efficiently.
Read more →SGHT▼ -6.5%on this newsshared move
Sight Sciences Launches the Ergo-Series of the OMNI Surgical System
Sight Sciences, Inc. has announced the U.S. launch of its Ergo-Series of the OMNI Surgical System, designed specifically for minimally invasive glaucoma procedures. The new system offers enhanced features, such as improved handle ergonomics and a new cannula tip design, which aim to facilitate better surgical access and performance. Medical professionals have praised these enhancements, noting their potential to improve patient care in glaucoma surgeries. The Ergo-Series is also set to be available outside of the U.S. later this year.
Read more →SGHTSight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
Sight Sciences, Inc. announced that it will report its financial results for the fourth quarter and full year of 2022 on March 13, 2023, after the market closes. The management team will hold a conference call to discuss these results at 1:30 p.m. PT. The company focuses on developing innovative eyecare solutions, including minimally invasive surgical devices targeting prevalent eye diseases. Investors can access the conference call live and it will be archived for later listening.
Read more →SGHTSight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
Sight Sciences, Inc. (Nasdaq: SGHT) will present at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York on March 1, 2023. The company's management will participate in a fireside chat, which can be accessed via a webcast on its investors' page. Sight Sciences aims to enhance eye care through innovative technology and solutions, including its OMNI® and TearCare® systems designed for glaucoma and dry eye diseases respectively.
Read more →SGHTSight Sciences Announces 1,000th TearCare Customer Installation
Sight Sciences announced the milestone of 1,000 installations of its TearCare® System, designed for treating evaporative dry eye disease caused by meibomian gland dysfunction. The system is FDA cleared and integrates localized heat therapy with manual expression of the meibomian glands. The company aims to improve patient access through ongoing clinical trials, including the SAHARA study, to further validate its efficacy compared to traditional pharmaceutical treatments. This growth reflects a strong confidence among eye care practitioners in the TearCare System's ability to address unmet needs in dry eye treatment.
Read more →SGHTSight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results Company Also Announces CFO Transition MENLO PARK, Calif.—
Sight Sciences, Inc. has announced preliminary unaudited financial results for Q4 and full year 2022, indicating significant revenue growth. The company reported a 40% increase in Q4 revenue and a 46% increase in annual revenue. Additionally, there is a transition in the CFO position, with the outgoing CFO providing consulting during the change. The final audited results will be disclosed in March 2023.
Read more →SGHTSight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper San
Read more →SGHT▲ +19.3%on this news· ran to +61% by day 1
Sight Sciences Reports Third Quarter 2022 Financial Results
Sight Sciences Reports Third Quarter 2022 Financial Results MENLO PARK, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' live
Read more →SGHTSight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majority of
Read more →SGHTSight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the third
Read more →SGHT▼ -7.7%on this news
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical Ophthalmology Study authors concluded that the TearCare procedure delivered superior symptoms improvements over LipiFlow in patients suffering from advan
Read more →SGHT▲ +5.9%on this newsshared move
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting
MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this
Read more →SGHT▼ -11%on this news
Sight Sciences OMNI Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Milan, Italy on
Read more →SGHTSight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasis
310-patient RCT designed to evaluate the superiority of TearCare® (device) vs Restasis® (drug) in patients with chronic dry eye disease is now fully enrolled 6-Month efficacy results expected by Summer 2023 MENLO PARK, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sight Sciences,
Read more →SGHTSight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the
Read more →SGHTSight Sciences Introduces the SION Surgical Instrument – The First Bladeless Device Used in Goniotomy Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure
Sight Sciences Introduces the SION Surgical Instrument The First Bladeless Device Used in Goniotomy Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure MENLO PARK, Calif., August 23, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.
Read more →SGHTSight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI Surgical System in Patients with Open Angle Glaucoma
MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced 36-month post-surgery fo
Read more →SGHTSight Sciences Reports Second Quarter 2022 Financial Results
Sight Sciences Reports Second Quarter 2022 Financial Results MENLO PARK, Calif., August 11, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives
Read more →SGHTSight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the secon
Read more →SGHT▲ +9.4%on this news· ran to +20% by day 3
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors
MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Tamara Fountain, M.D. to it
Read more →SGHTSight Sciences’ OMNI Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucoma These 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population MENLO PARK, Calif., M
Read more →SGHT▼ -8.6%on this news
Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandl
Read more →SGHTSight Sciences Reports First Quarter 2022 Financial Results
Sight Sciences Reports First Quarter 2022 Financial Results MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, to
Read more →SGHT▼ -5.2%on this news
Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that data from clinical studies of the OMNI®
Read more →SGHT▼ -5.2%on this newsshared move
Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022
MENLO PARK, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quar
Read more →SGHTSight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in th
Read more →SGHTSight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care a
Read more →SGHT▲ +5.7%on this news
Sight Sciences Announces Appointment of Brenda Becker to Board of Directors
MENLO PARK, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Brenda Becker to its Board
Read more →SGHTSight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
MENLO PARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quar
Read more →SGHTSight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting
MENLO PARK, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that data from clinical studies of the OMNI®
Read more →SGHTSight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference
MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcom
Read more →SGHT▼ -6.4%on this newsshared move
Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma
MENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced the launch of its “Don’t Wait for
Read more →SGHTSight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results MENLO PARK, Calif., January 10, 2022 (GLOBE NEWSWIRE) Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to trans
Read more →SGHTSight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration
Read more →SGHT▲ +11.1%on this news
Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Secu
Delivering the Power of Sight Investor Presentation December 2021 Exhibit 99.1 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of
Read more →SGHTSight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcom
Read more →SGHTSight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced that the Food and Drug Administra
Read more →SGHTSight Sciences Reports Third Quarter 2021 Financial Results
Sight Sciences Reports Third Quarter 2021 Financial Results MENLO PARK, Calif., November 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve p
Read more →SGHT▼ -7%on this news
Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the re
Read more →SGHTSight Sciences Announces TearCare Clinical Data Published in Cornea
MENLO PARK, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye diseases, today announced publication in the journal Cornea of positive r
Read more →SGHTSight Sciences Files Lawsuit Against Ivantis for Patent Infringement
MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10
Read more →SGHT▼ -11.2%on this news
Delivering the Power of Sight Investor Presentation September 2021 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain for
Delivering the Power of Sight Investor Presentation September 2021 1 Forward Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A o
Read more →SGHT▼ -5.3%on this news· ran to -21% by day 3shared move
Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced
Read more →SGHTSight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI Surgical System in Mild to Moderate Open-Angle Glaucoma
MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced
Read more →SGHTSight Sciences Reports Second Quarter 2021 Financial Results
Sight Sciences Reports Second Quarter 2021 Financial Results MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve pa
Read more →SGHTSight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company’s management will discuss the results during a c
Read more →SGHTSight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye diseases, today announced that data from multiple retrospective and prosp
Read more →SGHTSight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases, today announced
Read more →SGHTSight Sciences Announces Pricing of Initial Public Offering
MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the underlying causes of the world’s most prevalent eye diseases, today announced
Read more →Competitive Position
How SGHT ranks across every disease it competes inCompetitive Position is a premium feature
See how SGHT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial